Sugi Predict

Sugi Predict / Compounds / SCHEMBL951538

SCHEMBL951538

SCHEMBL951538

CC(C)(C)OC(=O)NC1CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.59
▸ MEN1 O00255 3/20 0.59
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ NPC1 O15118 2/20 0.58
▸ RAB9A P51151 2/20 0.58
▸ HTT P42858 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ L3MBTL1 Q9Y468 2/20 0.55
▸ KCNA3 P22001 1/20 0.53
▸ NPSR1 Q6W5P4 3/20 0.52
▸ MAPT P10636 2/20 0.52
▸ MAPK1 P28482 2/20 0.52
▸ NTSR1 P30989 1/20 0.52
▸ ENPP2 Q13822 1/20 0.52
▸ ALDH1A1 P00352 2/20 0.51
▸ GAA P10253 1/20 0.51
▸ GRIN2B Q13224 1/20 0.51
▸ HSD11B1 P28845 1/20 0.51
▸ PDE4B Q07343 1/20 0.51
▸ POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6590981 0.94 SMN1; SMN2 (0.58) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL2744899 0.94 KMT2A (0.53) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL1775260 0.93 HSD11B1 (0.59) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL1971844 0.93 HSD11B1 (0.59) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL953899 0.93 HSD11B1 (0.59) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL6580050 0.92 DRD2 (0.54) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL29259990 0.92 KMT2A (0.54) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL7870 0.91 L3MBTL1 (0.58) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL304546 0.91 SMN1; SMN2 (0.58) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL24705979 0.91 HSD11B1 (0.52) KMT2AMEN1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4685141-A1 ISOINDOLINE DERIVATIVE, BENZOINDOLE DERIVATIVE AND USE THEREOF Shanghai Helioson Pharmaceutical Co., Ltd. (CN) 2026-01-28 — — EP disclosed
EP-4594318-A1 AKT1 MODULATORS Alterome Therapeutics, Inc. (US) 2025-08-06 — — EP disclosed
US-20250092040-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2025-03-20 — — US disclosed
WO-2024193641-A1 ISOINDOLINE DERIVATIVE, BENZOINDOLE DERIVATIVE AND USE THEREOF 上海超阳药业有限公司 2024-09-26 — — WO disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-11999730-B1 AKT1 modulators ALTEROME THERAPEUTICS, INC. (US) 2024-06-04 — — US disclosed
US-20240174667-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-05-30 — — US disclosed
WO-2024107565-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-05-23 — — WO disclosed
WO-2024102621-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-05-16 — — WO disclosed
EP-0792289-A1 LOW MOLECULAR WEIGHT PEPTIDOMIMETIC GROWTH HORMONE SECRETAGOGUES GENENTECH, INC. (US) 1997-09-03 — — EP disclosed
US-5602138-A NKA affecting piperidyl heterobicyclic compounds ZENECA LIMITED (GB) 1997-02-11 — — US disclosed
US-5576333-A ASTHMA TREATMENT ZENECA LIMITED (GB) 1996-11-19 — — US disclosed
EP-0733051-A1 BICYCLIC HETEROCYCLES AS NEUROKININ A ANTAGONISTS ZENECA LIMITED (GB) 1996-09-25 — — EP disclosed
US-5559131-A ANTAGONISTS OF TACHYKININS AT THE NEUROKININ 2 RECEPTOR, ANTIASTHMA ZENECA LIMITED (GB) 1996-09-24 — — US disclosed
US-5559132-A ANTAGONIST OF TACHYKININS AT THE NEUROKININ 2 RECEPTOR, ANTIASTHMA ZENECA LIMITED (GB) 1996-09-24 — — US disclosed
WO-1996015148-A2 LOW MOLECULAR WEIGHT PEPTIDOMIMETIC GROWTH HORMONE SECRETAGOGUES GENENTECH, INC. (US) 1996-05-23 — — WO disclosed
EP-0667858-A1 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS ZENECA LIMITED (GB) 1995-08-23 — — EP disclosed
WO-1995015961-A1 BICYCLIC HETEROCYCLES AS NEUROKININ A ANTAGONISTS ZENECA LIMITED (GB) 1995-06-15 — — WO disclosed
WO-1994010146-A1 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS ZENECA LIMITED (GB) 1994-05-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239797-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 KMT2A 1301/4885MEN1 1284/4885SMN1; SMN2 2237/4885
US-20250092040-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 KMT2A 1301/4885MEN1 1284/4885SMN1; SMN2 2237/4885
US-11999730-B1 AKT1 modulators AKT1S1, AKT1, AKT2 KMT2A 1301/4885MEN1 1284/4885SMN1; SMN2 2237/4885
US-20240174667-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 KMT2A 1301/4885MEN1 1284/4885SMN1; SMN2 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.